Research.Patient.info

Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase II and Phase III (Integrated)
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK 009)
Hungary · Ireland · Spain